Targeted Alpha Therapy for Prostate Cancer, the Next Generation of Alpha-Emitting Radiopharmaceuticals
It’s hard to believe that it’s been nearly a decade since the ALSYMPCA trial with radium-223 was published, showing an overall survival benefit for men with bone metastatic castration-resistant prostate cancer and symptoms.1 Radium-223 is an alpha-particle emitting radiopharmaceutical that incorporates into areas of osteoblastic activity, with subsequent induction of double-strand DNA breaks in neighboring tumor cells. Although radium-223 has clear efficacy, one of the practical challenges of use is that prostate-specific antigen (PSA) level does not always decline in response to treatment and the association with clinical outcomes is poor. As a result, it is sometimes difficult for patients and health care providers to determine if radium-223 is working well or not.
Evan Y. Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
- Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
- Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.